Kolexia
Locher Chrystele Pneumologie
Locher Chrystele
Pneumologie
Clinique Saint Faron
Meaux, France
55 Activités
143 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Mésothéliome Mésothéliome malin Adénocarcinome Hypertension artérielle Carcinomes Protéinurie

Collaborateurs

Voir plus
Monnet Isabelle
Monnet Isabelle
Centre Hospitalier Intercommunal Créteil, Créteil, France
Chouaid Christos
Chouaid Christos
Centre Hospitalier Intercommunal Créteil, Créteil, France
Auliac Jean-Bernard
Auliac Jean-Bernard
Centre Hospitalier Intercommunal Créteil, Créteil, France
Moncelly Laurence
Moncelly Laurence
Clinique Saint Faron, Meaux, France

Industries

Voir plus
AstraZeneca
9 collaboration(s)
Dernière en 2023
Sanofi
3 collaboration(s)
Dernière en 2023
Boehringer Ingelheim
1 collaboration(s)
Dernière en 2023
GSK
1 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
1420P Real-life management of octogenarians with NSCLC in a French nationwide cohort
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
MAPS: A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM)
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   10 mars 2023
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).
Lung cancer (Amsterdam, Netherlands)   27 février 2023
Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.
Lung cancer (Amsterdam, Netherlands)   26 octobre 2022
Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studies.
The Lancet regional health. Europe   29 août 2022
Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study).
2022 ASCO Annual Meeting I   02 juin 2022
Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group.
Journal of thoracic disease   08 avril 2022
Circulating free tumor-derived DNA to detect mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study.
Journal of thoracic disease   08 avril 2022
PERSEE: Randomized, Open-label, Controlled Phase III Trial Comparing Pembrolizumab-platinum Based Chemotherapy Combination With Pembrolizumab Monotherapy in First Line Treatment of Non-small-cell Lung Cancers (NSCLC) With PDL1 Expression ≥50%
Essai Clinique (CHU Brest)   10 mars 2021
PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study.
Therapeutic advances in medical oncology   07 juillet 2020